[PDF][PDF] Radioactive iodine in the treatment of Graves' disease

JM Al-Kaabi, SS Hussein, CS Bukheit… - Saudi medical …, 2002 - researchgate.net
Objectives: This study was performed to evaluate the efficacy of radioactive iodine 131I therapy
of Graves’ hyperthyroidism at Sultan Qaboos University Hospital, Oman and to determine …

Activity of triciribine and triciribine-5′-monophosphate against human immunodeficiency virus types 1 and 2

…, SH PUCKETT, RW BUCKHEIT JR… - AIDS research and …, 1993 - liebertpub.com
Triciribine (TCN) and its 5′-monophosphate (TCN-P) are novel tricyclic compounds with
known antitumor activity; TCN-P is currently in phase II human clinical trials. We now report that …

Gap junction turnover is achieved by the internalization of small endocytic double-membrane vesicles

…, D Segretain, RW Buckheit III - Molecular biology of …, 2009 - Am Soc Cell Biol
… (A–C) High-resolution time-lapse recordings of Cx43-GFP GJ plaques acquired at relatively
fast acquisition rates (5 s in A and 6 s in B) reveal the internalization of small vesicles (…

Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV

KW Buckheit, C Furlan-Freguia… - Current Topics in …, 2016 - ingentaconnect.com
In the absence of an approved and effective vaccine, topical microbicides have become the
strategy of choice to provide women with the ability to prevent the sexual transmission of HIV…

Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy

RW Buckheit Jr - Expert Opinion on Investigational Drugs, 2004 - Taylor & Francis
The increasingly prevalent emergence of drug-resistant virus strains in patients being treated
with highly active antiretroviral regimens and the increasing rates of transmission of drug-…

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

…, MS Kay, KW Buckheit, RW Buckheit… - Retrovirology, 2013 - Springer
Background The limited success of recent HIV topical pre-exposure prophylaxis clinical trials
highlights the need for more predictive models of drug efficacy that better simulate what …

Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication

RW Buckheit Jr, JD Russell, ZQ Xu… - Antiviral Chemistry …, 2000 - journals.sagepub.com
… described (Buckheit et al., 1994b). The MacSynergy II program was obtained from Dr
Mark Prichard and Dr Charles Shipman at the University of Michigan (Ann Arbor, Mich., USA). …

[PDF][PDF] Development of a DuoGel for Vaginal and Rectal Delivery of Microbicide Products

K Buckheit, AD Boczar, CA Buchholz… - AIDS Research and …, 2014 - liebertpub.com
Background: It has been over 30 years since the first cases of HIV/AIDS and prevention of
infection through vaccination remains elusive. Thus, alternative products, technologies and …

[PDF][PDF] P15. 22 Fourteen-day Safety of Daily Vaginal Administration of Dapivirine-loaded Nanoparticles in a Mouse Model

K Buckheit, AD Boczar, CA Buchholz, S Nugent… - Development - researchgate.net
Background: We previously showed the ability of poly (ethylene oxide)-modified
polycaprolactone nanoparticles (PEO-PCL NPs) loaded with dapivirine to modulate genital …

Highly attenuated infection with a Vpr-deleted molecular clone of human immunodeficiency virus-1

…, DR Burton, RW Buckheit 3rd… - The Journal of …, 2018 - academic.oup.com
A 48-year-old woman was infected with a vpr-defective human immunodeficiency virus (HIV)-1
molecular clone. Seroconversion was markedly delayed, and without treatment she had …